No. 10: Stryker
2017 revenues: $12,444,000,000
2017 R&D spend: $787,000,000
Fiscal year ending: December 31, 2017
Kevin Lobo, chairman & CEO; Michael Hutchinson, general counsel; Yin Becker VP, communications, public affairs & strategic marketing; Bijoy Sagar, VP, CIO; Katherine Owen, VP, strategy & IR; Lonny Carpenter, president, global quality & business operations; Kathryn Fink, VP, HR; David Floyd, president, orthopedics; Timothy Scannell, president, medsurg & neurotechnology; William Jellison, VP, CFO
Although it’s a perennial name when the subject of M&A comes up as a potential acquiree, Stryker was active itself as an acquirer after closing the $700 million buyout of Novadaq a year ago. It bought French spinal implant maker Vexim for about $216 million, paid $664 million for minimally invasive sinus balloon maker Entellus Medical, picked up single-use-device reprocessor Hygia Health Services and acquired Swiss surgical smoke evacuation firm SafeAir. But it was the deal that never was that generated the most buzz: the rumor that it would acquire Boston Scientific in a move one analyst said could have formed a “higher-growth Medtronic.” The company’s Performance Solutions division got into the value-based healthcare game with the launch of the Practice Excellence program for orthopedic practices and readied a nearly $110 million facility in its home base of Michigan that’s slated to add as many as 260 jobs. On the personnel front, orthopedics president David Floyd is slated to retire next year, with Timothy Scannell as his replacement.